DE69636495D1 - Multi-tumor abweichende wachstumsgene - Google Patents

Multi-tumor abweichende wachstumsgene

Info

Publication number
DE69636495D1
DE69636495D1 DE69636495T DE69636495T DE69636495D1 DE 69636495 D1 DE69636495 D1 DE 69636495D1 DE 69636495 T DE69636495 T DE 69636495T DE 69636495 T DE69636495 T DE 69636495T DE 69636495 D1 DE69636495 D1 DE 69636495D1
Authority
DE
Germany
Prior art keywords
tumor
growth
gene
devoted
mag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69636495T
Other languages
English (en)
Other versions
DE69636495T2 (de
Inventor
Joern Bullerdiek
De Ven Jan Van
Franciscus Schoenmakers
Rafael Mols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69636495(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of DE69636495D1 publication Critical patent/DE69636495D1/de
Application granted granted Critical
Publication of DE69636495T2 publication Critical patent/DE69636495T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
DE69636495T 1995-02-17 1996-02-19 Multi-Tumor aberrante Wachstumsgene Expired - Fee Related DE69636495T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP95200390 1995-02-17
EP95200390 1995-02-17
EP95201951A EP0727487A1 (de) 1995-02-17 1995-07-14 Multi-Tumor abweichende Wachstumsgene
EP95201951 1995-07-14
PCT/EP1996/000716 WO1996025493A1 (en) 1995-02-17 1996-02-19 Multiple-tumor aberrant growth genes

Publications (2)

Publication Number Publication Date
DE69636495D1 true DE69636495D1 (de) 2006-10-12
DE69636495T2 DE69636495T2 (de) 2007-05-24

Family

ID=8220025

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69636495T Expired - Fee Related DE69636495T2 (de) 1995-02-17 1996-02-19 Multi-Tumor aberrante Wachstumsgene
DE0811061T Pending DE811061T1 (de) 1995-02-17 1996-02-19 Multi-tumor abweichende wachstumsgene

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0811061T Pending DE811061T1 (de) 1995-02-17 1996-02-19 Multi-tumor abweichende wachstumsgene

Country Status (14)

Country Link
US (3) US6544784B1 (de)
EP (3) EP0727487A1 (de)
JP (4) JPH11500614A (de)
KR (1) KR19980702276A (de)
AT (1) ATE338114T1 (de)
AU (1) AU4879096A (de)
CA (1) CA2213237A1 (de)
CZ (1) CZ247597A3 (de)
DE (2) DE69636495T2 (de)
FI (1) FI973354A (de)
HU (1) HUP9800028A3 (de)
NO (1) NO973685L (de)
PL (1) PL321831A1 (de)
WO (1) WO1996025493A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548122A1 (de) * 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6323329B1 (en) 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
AU748743B2 (en) * 1997-05-07 2002-06-13 University Of Medicine And Dentistry Of New Jersey Hmgi proteins in tumors and obesity
EP0878552A1 (de) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US6300127B1 (en) 1997-07-30 2001-10-09 Emory University Bone mineralization proteins, DNA, vectors, expression systems
WO1999057309A1 (en) * 1998-05-04 1999-11-11 Dako A/S Method and probes for the detection of chromosome aberrations
WO1999057012A2 (de) 1998-05-05 1999-11-11 Elau Elektronik Automations Ag Verpackungsmaschine
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DE19904514A1 (de) * 1999-02-04 2000-08-10 Joern Bullerdiek Mittel zur Prävention und/oder Behandlung von Leiomyomen
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1412754A4 (de) * 2001-06-27 2005-10-19 Inst Medical W & E Hall Diagnoseverfahren und -mittel
DE50212280D1 (de) * 2001-12-19 2008-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
WO2003087317A2 (en) * 2002-04-05 2003-10-23 Cyternex, Inc. Methods for targeting quadruplex dna
US20030219742A1 (en) * 2002-03-29 2003-11-27 Sanjay Bhanot Antisense modulation of HMGI-C expression
US7405041B2 (en) * 2002-08-20 2008-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for regulating transcription by targeting quadruplex DNA
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CN1878793A (zh) 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
CN101132811B (zh) 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
TW200902063A (en) 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
JP5366039B2 (ja) * 2008-03-18 2013-12-11 株式会社常光 悪性腫瘍の予想、診断のための方法および組成物
US20100297649A1 (en) * 2009-04-22 2010-11-25 Oliveira Andre M Methods and materials for detecting gene amplification
US20140248294A1 (en) 2011-10-05 2014-09-04 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
WO2016183679A1 (en) * 2015-05-21 2016-11-24 Université de Montréal Prognostic markers of acute myeloid leukemia survival

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
DE69033772T2 (de) * 1989-11-02 2002-06-20 Dictytech Pty Ltd Verbesserte plasmidvektoren für zelluläre schleimpilze der gattung dictyostelium
US5756307A (en) * 1991-09-20 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Sequence of human dopamine transporter cDNA
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer

Also Published As

Publication number Publication date
NO973685L (no) 1997-10-17
FI973354A0 (fi) 1997-08-15
FI973354A (fi) 1997-10-16
US20110318834A1 (en) 2011-12-29
AU4879096A (en) 1996-09-04
NO973685D0 (no) 1997-08-11
JP2008099698A (ja) 2008-05-01
EP0811061B2 (de) 2010-07-21
EP0811061B1 (de) 2006-08-30
EP1762619B1 (de) 2013-06-26
PL321831A1 (en) 1997-12-22
KR19980702276A (ko) 1998-07-15
EP0811061A1 (de) 1997-12-10
HUP9800028A2 (hu) 1998-04-28
EP0727487A1 (de) 1996-08-21
CZ247597A3 (cs) 1998-07-15
EP1762619A3 (de) 2007-05-09
CA2213237A1 (en) 1996-08-22
US6544784B1 (en) 2003-04-08
ATE338114T1 (de) 2006-09-15
DE811061T1 (de) 2002-10-17
WO1996025493A1 (en) 1996-08-22
EP1762619A2 (de) 2007-03-14
HUP9800028A3 (en) 2001-02-28
JP2007082549A (ja) 2007-04-05
JPH11500614A (ja) 1999-01-19
US20030190285A1 (en) 2003-10-09
JP2009254378A (ja) 2009-11-05
DE69636495T2 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
DE69636495D1 (de) Multi-tumor abweichende wachstumsgene
ATE125867T1 (de) Fibronektinbindungsprotein und dessen herstellung.
TR199501182A2 (tr) Pestisid özellikte yeni proteinler ve suslar.
ATE300613T1 (de) Menschliche, für zyklische nukleotide spezifische phosphodiesterase
CA2236166A1 (en) Enhancer-increased gene expression in plants
FI941048A (fi) Geloniinipolypeptidin koodaavia DNA-sekvenssejä
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
DK2256205T3 (da) Porphorymonas gingivalis-polypeptider og -polynukleotider
ATE120494T1 (de) Fibronectinbindungsprotein und dessen herstellung.
ATE387493T1 (de) Gene, die für proteine mit transglykolysierungsaktivität kodieren.
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
EP0769553A4 (de) Dna-fragment, rekombinanter vektor, der es enthält, und verfahren zur expression von fremdgenen mit seiner nutzung
DK0877758T3 (da) Oprenset SR-p70-protein
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
DE69934415D1 (de) Neuartiges collectin
EA199900893A1 (ru) Бактериальные плазмиды
DK1129191T3 (da) Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme
DE69739071D1 (de) Menschliche tak1 und für diese kodierende dna
DE69838459D1 (de) Für den licht-überempfinlichkeitsphaenotyp kodierende nukleotidsequenzen von tomaten, dadurch kodierte proteine und deren verwendungen
ATE301199T1 (de) Beta-primeverosidase gen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8339 Ceased/non-payment of the annual fee